BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 31681259)

  • 1. Engineered T Cell Therapy for Cancer in the Clinic.
    Zhao L; Cao YJ
    Front Immunol; 2019; 10():2250. PubMed ID: 31681259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
    Hiltensperger M; Krackhardt AM
    Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning the performance of CAR T cell immunotherapies.
    Richardson NH; Luttrell JB; Bryant JS; Chamberlain D; Khawaja S; Neeli I; Radic M
    BMC Biotechnol; 2019 Nov; 19(1):84. PubMed ID: 31783836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.
    Thibodeaux SR; Milone MC
    Clin Chem; 2019 Apr; 65(4):519-529. PubMed ID: 30593467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [T cell-based immunotherapies in solid tumors].
    Baulu E; Dougé A; Chuvin N; Bay JO; Depil S
    Bull Cancer; 2021 Oct; 108(10S):S96-S108. PubMed ID: 34920813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
    Sloas C; Gill S; Klichinsky M
    Front Immunol; 2021; 12():783305. PubMed ID: 34899748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
    Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
    IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
    Shum T; Kruse RL; Rooney CM
    Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR T cells: continuation in a revolution of immunotherapy.
    Singh AK; McGuirk JP
    Lancet Oncol; 2020 Mar; 21(3):e168-e178. PubMed ID: 32135120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
    Mao R; Hussein MS; He Y
    Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
    Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
    Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
    Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
    Front Immunol; 2018; 9():3062. PubMed ID: 30740109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
    Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V
    J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
    Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
    J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T-cell therapy for breast cancer.
    Gharghani MS; Simonian M; Bakhtiari F; Ghaffari MH; Fazli G; Bayat AA; Negahdari B
    Future Oncol; 2021 Aug; 17(22):2961-2979. PubMed ID: 34156280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.
    Lee YH; Kim CH
    Arch Pharm Res; 2019 Jul; 42(7):607-616. PubMed ID: 30830661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.